Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-23
2011-08-23
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S378000, C514S365000, C514S364000, C514S340000, C548S247000, C548S203000, C548S131000, C546S272100, C544S344000
Reexamination Certificate
active
08003648
ABSTRACT:
The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I:where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
REFERENCES:
patent: 3507881 (1970-04-01), Sandberg et al.
patent: 4760089 (1988-07-01), Chambers et al.
patent: 6037367 (2000-03-01), Christensen, IV et al.
patent: 6506757 (2003-01-01), Tajima et al.
patent: 6620832 (2003-09-01), Eastwood
patent: 6645939 (2003-11-01), Durette et al.
patent: 6710063 (2004-03-01), Chao et al.
patent: 6723740 (2004-04-01), Chao et al.
patent: 6875780 (2005-04-01), Auerbach et al.
patent: 6939875 (2005-09-01), Auerbach et al.
patent: 6964983 (2005-11-01), Auerbach et al.
patent: 7338960 (2008-03-01), Bell et al.
patent: 7345068 (2008-03-01), Endou et al.
patent: 7687526 (2010-03-01), Brown et al.
patent: 2004/0058965 (2004-03-01), Momose et al.
patent: 2005/0089866 (2005-04-01), Hinuma et al.
patent: 2005/0119256 (2005-06-01), Endo et al.
patent: 2006/0003344 (2006-01-01), Houseknecht et al.
patent: 2006/0004012 (2006-01-01), Akerman et al.
patent: 2006/0270724 (2006-11-01), Houze et al.
patent: 2007/0066647 (2007-03-01), Akerman et al.
patent: 2007/0142384 (2007-06-01), Akerman et al.
patent: 2007/0244155 (2007-10-01), Sharma et al.
patent: 2007/0265332 (2007-11-01), Ge et al.
patent: 2008/0090840 (2008-04-01), Beck et al.
patent: 2008/0119511 (2008-05-01), Brown et al.
patent: 2010/0075974 (2010-03-01), Beck et al.
patent: A 27141/77 (1979-01-01), None
patent: A 52306/93 (1994-06-01), None
patent: 2111035 (1994-06-01), None
patent: 199 41 567 (2000-04-01), None
patent: 0 250 264 (1987-12-01), None
patent: 0 414 289 (1994-02-01), None
patent: 1 357 115 (2003-10-01), None
patent: 1 380 562 (2004-01-01), None
patent: 1 535 915 (2005-06-01), None
patent: 1 559 422 (2005-08-01), None
patent: 1 630 152 (2006-03-01), None
patent: 10316641 (1998-02-01), None
patent: 2001242165 (2001-09-01), None
patent: 2002003368 (2002-01-01), None
patent: WO 93/23040 (1993-11-01), None
patent: WO 93/23041 (1993-11-01), None
patent: WO 95/01326 (1995-01-01), None
patent: WO 95/01348 (1995-01-01), None
patent: WO 97/12867 (1997-04-01), None
patent: WO 99/11255 (1999-03-01), None
patent: WO 00/63196 (2000-10-01), None
patent: WO 01/00603 (2001-01-01), None
patent: WO 01/36351 (2001-05-01), None
patent: WO 01/36365 (2001-05-01), None
patent: WO 02/057783 (2002-07-01), None
patent: WO 02/062774 (2002-08-01), None
patent: WO 02/100403 (2002-12-01), None
patent: WO 03/074050 (2003-09-01), None
patent: WO 03/099793 (2003-12-01), None
patent: WO 04/000315 (2003-12-01), None
patent: WO 2004/092117 (2004-10-01), None
patent: WO 2004/106276 (2004-12-01), None
patent: WO 2005/051890 (2005-06-01), None
patent: WO 2005/058848 (2005-06-01), None
patent: WO 2005/063725 (2005-07-01), None
patent: WO 2005/063729 (2005-07-01), None
patent: WO 2005/086661 (2005-09-01), None
patent: WO 2005/087710 (2005-09-01), None
patent: WO 2006/001092 (2006-01-01), None
patent: WO 2006/011615 (2006-02-01), None
patent: WO 2006/083612 (2006-08-01), None
patent: WO 2006/083781 (2006-08-01), None
patent: WO 2007/123225 (2007-11-01), None
patent: WO 2007/131619 (2007-11-01), None
patent: WO 2007/131620 (2007-11-01), None
patent: WO 2007/131622 (2007-11-01), None
Bachmann, W. E. et al., “The Synthesis of an Analog of the Sex Hormones,”J. Am. Chem. Soc., 64, 94-97 (1942).
Berthelot et al., “Synthesis and Pharmacological Evaluation of y-Aminobutyric Acid Analogues. New Ligand for GABAa Sites,”J. Med. Chem., 30, 743-746 (1987).
Booth, C. J. et al., “The Synthesis and Transition Temperatures of Novel Low Molar Mass Chosesteric materials Derives from (R)-2-(4-Hydroxyphenoxy)propanoic Acid,” Mol. Cryst. Liq. Cryst., vol. 210, pp. 31-57 (1992).
Booth, C. J. et al., “The Influence of the Liquid Crystalline Core Geometry on the Mesogenicity of Novel Chiral 2-(4-Substituted-phenoxy)propanonitriles,” Liquid Crystals, vol. 16(6), pp. 925-940, (1994).
Boyle, Thomas F. et al., “Applications of the Spiroannulation of Tetralins with Alkynes; Towards New Anti-Estrogenic Compounds,”J. Chem. Soc. Perkin Trans. I: Organic and Bioorganic Chem., 18, 2707-2711 (1997).
Briscoe et al., “The Orphan G Protein-Coupled Receptor GPR40 is Activated by Medium and Long Chain Fatty Acids,”J. of Biol. Chem., 278(13), 11303-11311 (2003).
Briscoe, C. P. et al., “Pharmacological Regulation of Insulin Secretion in MIN6 Cells Through the Fatty Acid Receptor GPR40: Identification of Agonist and Antagonist Small Molecules,”Brit. J. of Pharmacology, 148, 619-628 (2006).
Burnop, V.C.E. et al., “Fused Carbon Rings. Part XIX. Experiments on the Synthesis of Tetracyclic Compounds of the Sexual Hormonal Type,”J. Chem. Soc., 727-735 (1940).
Chatterjee, A., et al., “Studies on Nucleophilic Ring Opening of Some Epoxides in Polar Protic Solvents,”Tetrahedron, 33, 85-94 (1977).
Collins, David J. et al., “The Structure and Function of Oestrogens. IX. Synthesis of the trans Isomer of 5,5,10b-Trimtehyl-4b,5,6,10b,11,12-hexahydrocvhrysene-2,8-diol,”Aust. J. Chem., 41, 735-744 (1988).
Deb, Soumitra et al., “A Stereocontrolled Synthesis of (1′RS,2′SR)-3-oxo-3′,4′-dihydrospiro[cyclopentane-1,1′(2′H)-naphthalen]-2-yl Acetic Acid and its Methoxy Derivatives,”J. Chem. Res. Synops., 12, 406 (1985).
DeWolf et al., “Inactivation of Dopamine β-Hydroxylase by β-Ethynyltyramine: Kinetic Characterization and Covalent Modification of an Active Site Peptide,”Biochemistry, 28, 3833-3842 (1989).
Egan, R. W. et al., “Naphthalenes as Inhibitors of Myeloperoxidase: Direct and Indirect Mechanisms of Inhibition,”Agents and Actions, 29 3/4 266-276 (1990).
Frey et al., “Total Synthesis of Pentacyclic Diterpenoid Tropone Hainanolidol,”Aust. J. Chem., 53, 819-830 (2000).
Galemmo et al., “The Development of a Novel Series of (Quinolin-2-ylmethoxy) phenyl-Containing Compounds as High-Affinity Leukotriene Receptor Antagonists. 3. Structural Variation of the Acidic Side Chain to Give Antagonists of Enhanced Potency,”J. Med. Chem., 33, 2828-2841 (1990).
Garrido, D. M., et al., “Synthesis and Activity of Small Molecule GPR40 Agonists,”Bioorg. and Med. Chem. Lett., 16, 1840-1845 (2006).
Ghosal, Probir Kumar, et al., “Stereospecific Synthesis of 9bβ-Carbomethoxy-7-methoxy-2,3,3aα,4,5,9bβ-Hexahydro-1H-Benz[e]-Inden-2-one; An Intermediate Towards Physiologically Active Compounds,”Tet. Lett., 17, 1463-1464 (1977).
Guthrie, R. W. et al., “Synthesis in the Series of Diterpene Alkaloids VI. A Simple Synthesis of Atisine,”Tet. Lett., 38, 4645-4654 (1966).
Haigh et al., “Non-thiazolidinedione Antihyperglycaemic Agents. Part 3: The Effects of Stereochemistry on the Potency of α-Methoxy-β-phenylpropanoic Acids,”Bioorg. and Med. Chem., 7, 821-830 (1999).
Hares, Owen et al., “Sythetic Studies of Tricyclospirodienones: Model Chemistry for Novel Mimics of Steroid Substrates,”J. Chem. Soc. Perkin Trans. I: Organic and Bioorganic Chem., 13, 1481-1492 (1993).
Houze, J. et al., “Beta-substituted Carboxylic Acids as Potent, Bioavailable Agonists of GPR40”, 234thACS National Meeting Boston, MA Aug. 19-23, 2007.
Iizuka et al., “β-Substituted Phenethylamines as High Affinity Mechanism-Based Inhibitors of Dopamine β-Hydroxylase,”J. Med. Chem., 31, 704-706 (1988).
Ishikawa et al., “Actions of the Novel Oral Antidiabetic Agent HQL-975 in Insulin-Resistant Non-Insulin—Dependent Diabetes Mellitus Model Animals,”Diabetes Res. and Clin. Pract., 41, 101-111 (1998).
Ishikawa et al., “Effects of t
Beck Hilary
Dransfield Paul
Fu Zice
Houze Jonathan B.
Jiao XianYun
Amgen Inc.
Chu Yong
Friedrichsen Bernard P.
LandOfFree
Heterocyclic GPR40 modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic GPR40 modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic GPR40 modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2631940